A securities class action has been filed in the USDC — MA. against Zenas BioPharma, Inc. (ZBIO) (“Zenas BioPharma” or the “Company”) securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (the “IPO” or “Offering”).

Defendant Zenas BioPharma purports to be a “clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need.”

The Complaint alleges that the Registration Statement contained false and/or misleading statements and/or failed to disclose that:

(1) Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and

(2) as a result, Defendants’ public statements were materially false and misleading at all relevant times and negligently prepared, thereby harming investors.

If you purchased Zenas BioPharma securities pursuant and/or traceable to the registration statement issued in connection with Zenas BioPharma’s September 2024 IPO and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.